Reporting of side-effects in clinical trials of psilocybin-assisted psychotherapy for psychiatric conditions: systematic review
BJPsych Open · 2025-11 · 11 (6)
DOI: 10.1192/bjo.2025.10847 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift BJPsych Open, online erschienen am 03.11.2025. Verfasst von Jonathon Marinis und 4 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Youth Mental Health, https://ror.org/01ej9dk98University of Melbourne and Orygen, Australia. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Psilocybin-assisted psychotherapy (PAP) has gained attention as a promising intervention for conditions including depression, anxiety and post-traumatic stress disorder, but understanding of its side-effects is limited. This review evaluates the quality of side-effects reporting in PAP trials, to guide treatment, policy and research.
Aims
To assess side-effects reporting quality in PAP trials for psychiatric conditions, comparing published articles and ClinicalTrials.gov records.
Method
A PROSPERO-registered review (no. CRD42023458960) included English-language PAP trials (2005–2024) identified via Embase, CENTRAL, PubMed and reference searches. Reporting quality was assessed using the CONSORT Harms extension, categorised as either high (17–21), moderate (12–16), low (7–11) or very low (0–6). Randomised controlled trials underwent risk of bias analysis, and descriptive statistics compared side-effects across sources.
Results
Twenty-four trials were included. Reporting quality was high in six studies, moderate in four, low in nine and very low in five. All randomised controlled trials ( n = 9) showed high risk of bias for side-effects outcomes. Variability in reporting hindered comparisons between articles and ClinicalTrials.gov, underscoring the need for standardisation. Overall, there was no evidence of systematic underreporting of side-effects in published articles compared with trial registers.
Conclusions
Side-effects reporting in PAP trials is inconsistent but is improving over time. Existing evidence has a high risk of bias. Future trials should align with best-practice guidelines for side-effects reporting. Discussions with patients should prioritise findings from high-quality studies and emphasise the current uncertainty regarding PAP side-effects.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Centre for Youth Mental Health, https://ror.org/01ej9dk98University of Melbourne and Orygen, Australia.
- Clinic for Autism and Neurodevelopmental Research, Brain and Mind Centre, Children's Hospital Westmead Clinical School, Faculty of Medicine and Health, University of Sydney, Australia.
ORCID-Profile: Jonathon Marinis, Adam J Guastella, Gillinder Bedi
Zitieren
APA
Marinis, J., Clarke, S. T., Guerin, A. A., Guastella, A. J., & Bedi, G. (2025). Reporting of side-effects in clinical trials of psilocybin-assisted psychotherapy for psychiatric conditions: systematic review. BJPsych Open, 11(6). https://doi.org/10.1192/bjo.2025.10847
Vancouver
Marinis J, Clarke ST, Guerin AA, Guastella AJ, Bedi G. Reporting of side-effects in clinical trials of psilocybin-assisted psychotherapy for psychiatric conditions: systematic review. BJPsych Open. 2025;11(6). doi:10.1192/bjo.2025.10847
BibTeX
@article{Marinis2025,
author = {Marinis, Jonathon and Clarke, Sarah T and Guerin, Alexandre A and Guastella, Adam J and Bedi, Gillinder},
title = {Reporting of side-effects in clinical trials of psilocybin-assisted psychotherapy for psychiatric conditions: systematic review},
journal = {BJPsych Open},
year = {2025},
volume = {11},
number = {6},
doi = {10.1192/bjo.2025.10847}
}
EUVIMED